TW201016694A - Hepatitis C inhibitor compounds - Google Patents

Hepatitis C inhibitor compounds Download PDF

Info

Publication number
TW201016694A
TW201016694A TW098131961A TW98131961A TW201016694A TW 201016694 A TW201016694 A TW 201016694A TW 098131961 A TW098131961 A TW 098131961A TW 98131961 A TW98131961 A TW 98131961A TW 201016694 A TW201016694 A TW 201016694A
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
group
doc
cycloalkyl
Prior art date
Application number
TW098131961A
Other languages
English (en)
Chinese (zh)
Inventor
Jeffrey O'meara
Josee Bordeleau
Vida Gorys
Melissa Leblanc
Kirsten Lenhardt
Montse Llinas-Brunet
Mathieu Parisien
Marc-Andre Poupart
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW201016694A publication Critical patent/TW201016694A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW098131961A 2008-09-23 2009-09-22 Hepatitis C inhibitor compounds TW201016694A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9929208P 2008-09-23 2008-09-23
US18663209P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
TW201016694A true TW201016694A (en) 2010-05-01

Family

ID=42059237

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098131961A TW201016694A (en) 2008-09-23 2009-09-22 Hepatitis C inhibitor compounds

Country Status (6)

Country Link
EP (1) EP2344487A4 (fr)
JP (1) JP2012502925A (fr)
AR (1) AR073659A1 (fr)
CA (1) CA2737958A1 (fr)
TW (1) TW201016694A (fr)
WO (1) WO2010034105A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009303483A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
BR112013016480A2 (pt) 2010-12-30 2016-09-20 Abbvie Inc macrocíclo da fenantridina inibadores da protease da serina da hepatite c
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (fr) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2964664B1 (fr) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370396A1 (fr) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
CN103204903A (zh) * 2003-05-21 2013-07-17 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
CA2568008C (fr) * 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Processus de preparation d'inhibiteurs de protease hcv acyclique
EP1763531A4 (fr) * 2004-06-28 2009-07-01 Boehringer Ingelheim Int Analogues peptidiques d'inhibiteurs de l'hepatite c
AU2008271116B2 (en) * 2007-06-29 2012-09-20 Gilead Sciences, Inc. Antiviral compounds
CN101801925A (zh) * 2007-06-29 2010-08-11 吉里德科学公司 抗病毒组合物
WO2009076173A2 (fr) * 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Composés à base de tripeptides fluorés inhibant la sérine protéase du vhc

Also Published As

Publication number Publication date
CA2737958A1 (fr) 2010-04-01
EP2344487A1 (fr) 2011-07-20
EP2344487A4 (fr) 2012-03-21
AR073659A1 (es) 2010-11-24
JP2012502925A (ja) 2012-02-02
WO2010034105A1 (fr) 2010-04-01
WO2010034105A8 (fr) 2011-01-06

Similar Documents

Publication Publication Date Title
TW201016694A (en) Hepatitis C inhibitor compounds
US7767818B2 (en) Hepatitis C inhibitor dipeptide analogs
ES2366478T3 (es) Análogos peptídicos inhibidores de la hepatitis c.
CA2615921C (fr) Analogues de peptides inhibiteurs de l'hepatite c comprenant une partie de quinoleine ou de thienopyridine
EP1730167B1 (fr) Peptides macrocycliques actifs contre le virus de l'hepatite c
JP4914348B2 (ja) Ｃ型肝炎インヒビターペプチド類似体
JP4704342B2 (ja) Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
TW200307680A (en) Hepatitis C inhibitor compound
AU2005263135A1 (en) Viral polymerase inhibitors